PALM BEACH, Florida, March 28, 2017 /PRNewswire/ --

The Global Regenerative Medicine Market is expected to observe the highest growth coming from the Tissue Engineering segment. By technology type, biomaterial segment currently holds the largest market share of global regenerative medicine market. However, Tissue Engineering segment is anticipated to be the fastest growing segment over the forecast period. In terms of value, the tissue engineering segment market is expected to expand at an outstanding CAGR of 17.5% over the forecast period of 2015-2019, to reach a market value of about US$ 1,070 Mn by 2019. Biotech companies in the news this week with developments of note or market performances include: RepliCel Life Sciences Inc. (OTC: REPCF)(TSXV: RP.V), Impax Laboratories, Inc. (NASDAQ: IPXL), Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), Aevi Genomic Medicine, Inc. (NASDAQ: GNMX), U.S. Stem Cell, Inc. (OTC: USRM)

RepliCel Life Sciences Inc. (OTCQB: REPCF)(TSX-V: RP) is pleased to report compelling safety and clinical data from its phase 1/2 tendon repair study investigating the use of RepliCel's type 1 collagen-expressing, hair follicle-derived fibroblasts (RCT-01) as a treatment for Achilles tendinosis. The clinical trial met its goal of establishing a complete safety profile at 6 months and showed no serious adverse events related to the study treatment or injection procedure.

Additionally, each of the treated participants, all of whom suffered chronic tendon pain and loss of function over an extended period of time with no recovery from standard treatments, showed numerous clinically important improvements by various measures including tendon composition, blood supply, physical function and pain sensation. Read this in its entirety and more news for RepliCel Life Sciences at: http://marketnewsupdates.com/news/repcf.html

"Chronic tendinosis is a state of tendon degeneration that is very difficult to reverse as is borne out by the many therapies and modalities that are used to try and treat it," stated Dr. Ross Davidson, an orthopedic surgeon, former clinical professor at the Department of Orthopaedics at the University of British Columbia, and past head physician and orthopaedic consultant for the Vancouver Canucks (of the National Hockey League (NHL)). "This study shows exciting clinical improvements in patients with clinically diagnosed chronic Achilles tendinosis who were unresponsive to standard treatments, and who had suffered for many months (in some cases, years) with frequent pain and loss of function. Not only did the study show several clinically important improvements in pain and function scores, but several ultrasound measures clearly demonstrate a marked improvement in tendon structure; something rarely seen in patients with this condition," said Davidson.

In other biomedicine/biotech news and developments: 

Impax Laboratories, Inc. (NASDAQ: IPXL) closed up over 37% on Monday at $12.70 trading over 12.2 Million shares by the market close. Impax Laboratories, Inc. yesterday announced that its Board of Directors has appointed Paul M. Bisaro as Impax's President and Chief Executive Officer and a member of the Company's Board, effective March 27, 2017. Mr. Bisaro will succeed J. Kevin Buchi, who has served as Interim President and Chief Executive Officer since December of 2016. With 25 years of generic and branded pharmaceutical experience, Mr. Bisaro, 56, is an accomplished global business leader who brings a successful record of leading operational execution and corporate transformation, resulting in company growth.

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) closed up on MOnday at $2.55 trading over 5 Million shares by the market close. Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States.

Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) closed up over 15% on MOnday at $1.85 trading over 2.2 Million shares by the market close. Aevi Genomic Medicine, Inc. last week announced top-line results from the SAGA trial of AEVI-001 (oral non-stimulant) in adolescents with mGluR mutation positive (mGluR+) ADHD. AEVI-001 represents a novel paradigm of genomic diagnosis and treatment in neuropsychiatric disorders. The mGluR predictive biomarker enabled study of AEVI-001 in an adolescent ADHD sub-population with genetic mutations that disrupt the mGluR network and result in glutamate imbalance.

U.S. Stem Cell, Inc. (OTCQB: USRM) closed up over 25% on MOnday trading over 35.5 Million shares by the market close. U.S. Stem Cell announced earlier this month the following results from operations for the year ending December 31, 2016. "U.S. Stem Cell, Inc. continues to increase revenue, decrease liabilities, and decrease operating expenses," said Mike Tomás, President and CEO of U.S. Stem Cell, Inc. "As a world leader in stem cell research and development for degenerative conditions, we are excited about the industry's future and dedicated to making a positive impact in our patients' lives." Working with physician partners to offer over 30 protocols to patients, U.S. Stem Cell, Inc. is increasing business opportunities by expanding its services, treatments, and therapies both inside and outside the United States. Read the news in its entirety at http://finance.yahoo.com/news/u-stem-cell-releases-positive-210000866.html

DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU has been compensated six thousand nine hundred dollars for news coverage of the current press release issued by RepliCel Life Sciences Inc. by the company. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.

Contact Information:
Media Contact email: info@marketnewsupdates.com - +1(561)325-8757

SOURCE MarketNewsUpdates.com